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ABSTRACT
Background
A soluble form of endothelial cell protein C receptor (sEPCR) is generated by shedding of the
cellular form. sEPCR binds to protein C and factor VIIa and inhibits both the activation of pro-
tein C and the activity of activated protein C and factor VIIa. High sEPCR levels may increase
the risk of thrombosis. We wanted to explore the possibility of detecting soluble endothelial cell
protein C receptor forms generated by alternative splicing.
Design and Methods
Reverse transcriptase polymerase chain reaction was used to look for new forms of endothelial
cell protein C receptor. A yeast expression system was used to generate sufficient amounts of
the distinct sEPCR forms. Surface plasmon resonance experiments, chromogenic assays, clot-
ting assays and immunoassays were subsequently performed to characterize a new form of
sEPCR that was found.
Results
We demonstrated, by reverse transcriptase polymerase chain reaction and sequencing, the exis-
tence of a new, soluble form of endothelial cell protein C receptor generated by alternative splic-
ing, in which the transmembrane region is replaced by a 56-residue tail (tEPCR). Its cDNA was
present in human umbilical vein endothelial cells and in most tissues as well as in lung cancer
cells. tEPCR was not located in the membrane of transfected cells.We demonstrated that tEPCR
binds to protein C and factor VIIa. tEPCR blocked the generation of activated protein C and
inhibited the activity of both activated protein C and factor VIIa. tEPCR was detected, by
immunoassays, in the supernatant of lung cancer cells and human umbilical vein endothelial
cells.
Conclusions
A truncated form of alternatively spliced endothelial cell protein C receptor was detected in the
endothelium and cancer cells. tEPCR behaves as sEPCR generated by shedding of the cellular
endothelial cell protein C receptor.
Key words: endothelial protein C receptor, endothelium, protein C, factor VIIa, alternative
splicing.
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Introduction
The endothelial cell protein C receptor (EPCR) plays
an anticoagulant role in hemostasis. Expressed mainly
on the surface of the endothelium of large vessels and
the trophoblast, EPCR binds protein C with high affin-
ity (KD ~ 30 nM) and increases, by more than 10-fold,
the generation of activated protein C (APC) by the
thrombin-thrombomodulin complex.1,2 We have
shown that EPCR also binds to factor VIIa and inhibits
its coagulant activity.3
A soluble form of EPCR (sEPCR) comprising the
extracellular domain and lacking the rest of its domains
has been identified in human plasma.4 In most healthy
subjects the concentration of sEPCR is between 100-200
ng/mL, but the levels are between 250-500 ng/mL in
20% of individuals.5 These higher levels of sEPCR are
associated with one of the four EPCR haplotypes, A3,
defined by a variation in the coding sequence of EPCR
and resulting in the substitution of a serine with a
glycine at position 219 in the transmembrane domain.6
This haplotype promotes cellular shedding by tumor
necrosis factor-α converting enzyme/ADAM17
(TACE).7 High levels of sEPCR have been postulated to
be associated with an increased risk of venous thrombo-
sis,6 but the data are controversial and two big studies
failed to find an association.8,9 sEPCR blocks protein C
activation by preventing protein C from binding to
membrane EPCR. The binding of sEPCR to APC also
blocks the proteolytic activity of APC on factors Va and
VIIIa.4 sEPCR acts as a decoy receptor that antagonizes
the effects of cell surface EPCR and is, thus, considered
to be a procoagulant molecule. However, our recent
findings showing that sEPCR blocks factor VIIa activity
suggest that it may also have an anticoagulant effect.3
EPCR is a glycoprotein consisting of an extracellular
region, a transmembrane domain, and a small cytoplas-
mic tail. Exon 1 codes for the 5’ untranslated region and
the signal peptide. Exons 2 and 3 code for most of the
extracellular region and exon 4 codes for the transmem-
brane domain, the intracytoplasmatic tail, and the 3’
untranslated region.10 Alternative pre-mRNA splicing is
an important mechanism for regulating gene expres-
sion in higher eukaryotes. Until recently, the above
described EPCR, arising from normal intron–exon splic-
ing, was the only mature protein product found to arise
from the EPCR gene. While our study was in progress,
Saposnik et al. reported the occurrence of a new form
of sEPCR generated by alternative splicing.11 The
results presented in the current work are coherent with
theirs, and provide additional information about the
detection of this new form of sEPCR in endothelial and
neoplastic cells.
Design and Methods
Reverse transcription polymerase chain reaction to
examine EPCR expression
RNA was extracted from human umbilical cord vein
endothelial cells (HUVEC) and a reverse transcription
reaction to obtain cDNA was performed according to
standard procedures.12 The expression of the EPCR
gene was analyzed by the PCR technique with primers
(Genset, Paris, France) spanning the 5’and 3’ untranslat-
ed regions: primer 5’: 5’-GAACCCAGGTCCGGAGC-
CTCAAC-3’; and primer 3’: 5’-ACATTTCCACCA-
CTTCTTCGTGTTAC-3’.
Since, using this method, we identified a band of 834
bp in addition to the 1221 bp band corresponding to
the normal spliced transcript, we wanted to determine
whether the alternatively spliced form of EPCR could
also be detected in sources other than HUVEC.
Therefore, a cDNA library of different human tissues
(multiple tissue cDNA [MTC] panels I and II; BD
Biosciences, San Jose, CA, USA) and cDNA from a vari-
ety of lung cancer cell lines (H44, H510, H1264, A549,
H441, HTB51, H676, H727, H720, H385, and H1299,
generously provided by Dr. F. Lecanda [University of
Navarra, Spain]) were studied. For this purpose, a PCR
was set up to amplify a shorter fragment of the EPCR
gene using primers suitable fot detecting both wild-
type and alternatively spliced forms. The primers used
(Genset) were: primer 5’: 5’-GCAGTATGTGCA-
GAAACATATTTCCGC-3’; and primer 3’: 5’-
CATCCCAAGTCTGACACACCTGGAAGT-3’.
With this method two bands of 578 bp and 189 bp,
corresponding to the wild-type and alternatively
spliced forms, respectively, were observed.
Sequencing of the alternatively spliced EPCR
transcript
The lower band detected in HUVEC was re-ampli-
fied following the same amplification conditions. The
amplified product was rescued from the agarose gel
using QIAquick Gel Extraction Kit (Qiagen, Valencia,
CA, USA), and used in turn as a template for the
sequence reaction (ABI PRISM, Applied Biosystems,
Foster City, CA, USA). Two sequence reactions were
performed with the primers used in the original reverse
transcription-PCR which originated a fragment of 834
bp. The reaction products were analyzed in an ABI
PRISM® 377 DNA Sequencer (Applied Biosystems).
Expression in mammalian cells of EPCR and truncat-
ed EPCR fused with green fluorescent protein (GFP)
Sequencing of the lower band revealed that this was
generated by alternative splicing of EPCR pre-mRNA
which had eliminated part of exon 4 from the transcript
(see Results). The cDNA of both tEPCR and EPCR were
cloned into the pcDNA3.1/CT-GFP-TOPO vector
(Invitrogen, Carlsbad, CA, USA), according to the man-
ufacturer’s instructions. COS-7 cells (ECACC,
Salisbury, England) were propagated in DMEM supple-
mented with 10% fetal calf serum. Transfections were
performed in 35-mm well plates, using the lipofecta-
mine method (Lipofectamine 2000, Invitrogen) with 1
µg/well of each expression plasmid linearized with Kpn
I (New England Biolabs, Ipswich, MA, USA). Twenty-
four hours after transfection, the cells were washed
with phosphate-buffered saline and the sub-cellular
localization of tEPCR-GFP or EPCR-GFP was analyzed
by fluorescence microscopy in an Eclipse TE3000
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inverted microscope (Nikon, Badhoevedorp, The
Netherlands).
Cloning and expression of tEPCR in Pichia pastoris
The tEPCR cDNA was amplified and integrated
between the ClaI and NotI sites of the pPICZαC plasmid
(Invitrogen) after the factor α secretion signal of
Saccharomyces cerevisiae. Due to the cloning process, a ser-
ine and an isoleucine residue were added at the amino-
terminus of the tEPCR. After checking by direct sequenc-
ing that the tEPCR sequence was correctly inserted, the
vector was used to transform Pichia pastoris cells accord-
ing to previously described methods.13 Recombinant
tEPCR was purified from yeast supernatants using a
three-step purification: hydrophobic interaction, anion
exchange and immunoaffinity using the rat anti-human
EPCR monoclonal antibody RCR-2, provided by Dr. K.
Fukudome (Saga University, Saga, Japan).
The soluble EPCR residues 1-193, mature protein
numbering,10 were also expressed in Pichia pastoris and
purified as described previously.3
Biomolecular interaction analysis by surface plasmon
resonance
The interaction between both EPCR forms (tEPCR
and sEPCR) and their ligands was studied by surface
plasmon resonance in a BIAcore X Biosensor (BIAcore
AB, Uppsala, Sweden). tEPCR and sEPCR were cap-
tured by the anti-EPCR monoclonal antibody RCR-2
immobilized on a CM5 chip (BIAcore). Factor VII
(Enzyme Research Laboratories, South Bend, IN, USA)
or VIIa (Novo Nordisk, Bagsvaerd, Denmark) was
injected in a Hepes buffer with 3 mM CaCl2, and 0.6
mM MgCl2 (HBS-T). Protein C and APC (Enzyme
Research Laboratories) binding to sEPCR was also ana-
lyzed under the conditions used to study the binding of
factor VII/VIIa. Kinetic and affinity analyses were per-
formed using BIAEVALUATION software 3.2 RC1
(BIAcore).
Activation of protein C on the surface of endothelial
cells
EA.hy926 cells (an endothelium-derived cell line,
kindly supplied by Dr. CJ Edgell, University of North
Carolina, USA) were incubated with 0.17 nM thrombin
(ERL, Swansea, UK) and increasing concentrations of
protein C ranging between 50 and 1000 nM in a 20 mM
Tris buffer, pH 7.4, supplemented with 150 mM NaCl,
5 mM CaCl2, 0.6 mM MgCl2, 1% bovine serum albu-
min, 0.01% Tween-20 and 0.02% NaN3. After 45 min-
utes lepirudin (Schering AG, Berlin, Germany) was
added at a concentration of 0.2 µM to inhibit thrombin
and 4 minutes afterwards 0.4 mM of the chromogenic
substrate S-2366 (Chromogenix, Milan, Italy) was
added and its proteolysis by APC kinetically monitored
at 405 nm in the iEMS Reader. Initial rates (Vo) were
calculated for each condition and the data curve fitting
the Michaelis-Menten equation was constructed using
Enzfitter software (Biosoft, Cambridge, UK) which cal-
culated the Km and Vmax values of protein C activa-
tion under these conditions. When required, tEPCR or
sEPCR was added. 
Effect of tEPCR on anticoagulant activity of APC 
measured by the activated partial thromboplastin time 
The clotting of pooled normal human plasma (100 µL)
supplemented with 1 nM APC was initiated by adding
the reagent, Pathrombin (Dade Behring, Schwalbach,
Germany). The clotting times in the presence of increas-
ing amounts of tEPCR or sEPCR were recorded in a STA
automated coagulometer (Roche Diagnostics,
Boehringer Mannheim, Mannheim, Germany). 
Effect of tEPCR on coagulant activity of factor VIIa
Factor VIIa, factor X and tissue factor-expressing H727
cells were incubated for 5 minutes in the absence or
presence of sEPCR or tEPCR. Factor VIIa activity was
arrested with 12.5 mM EDTA and factor Xa generation
was estimated by proteolysis of  S-2765 (Chromogenix).3
Preparation of monoclonal antibodies against tEPCR
and enzyme linked immunosorbent assay (ELISA) 
to measure tEPCR levels
BALB/c mice were immunized with tEPCR and their
spleen cells fused with NS-1 cells (ECACC) according to
standard procedures. Once the monoclonality of the
hybridomas had been assured, the monoclonal antibod-
ies which detected tEPCR without cross-reaction with
sEPCR were selected and two of them, MAVE-1 and
MAVE-3, chosen to set up a sandwich ELISA to measure
tEPCR in plasma and cell culture supernatants. MAVE-1
was used as the coating monoclonal antibody at a con-
centration of 5 µg/mL and MAVE-3 was biotinylated
(Pierce, Rockford, IL, USA) and used at a concentration
of 5 µg/mL as the detecting monoclonal antibody prior
to the addition of streptavidin-horseradish peroxidase
(GE Healthcare) and SuperSignal ELISA Femto
Maximum Sensitivity Substrate (Pierce). A standard
curve was constructed with known amounts of recom-
binant tEPCR. The signal obtained was measured in a
Luminoskan Ascent reader (Thermo Labsystems,
Waltham, MA, USA). The detection limit of the assay
was 0.125 nM. tEPCR levels were measured with this
assay in the supernatants of lung adenocarcinoma A549
and H1264 cells, which had been shown to express
tEPCR at the cDNA level. MAVE-3 was also used to
detect tEPCR by western blotting in the conditioned
culture medium of HUVEC.
Total soluble EPCR levels were measured by a com-
mercial test (Asserachrom sEPCR, Diagnostica Stago,
Asnières, France).
Results
An alternatively spliced form of EPCR is found in
cDNA of HUVEC
To determine whether alternative forms of EPCR could
be detected, reverse transcription-PCR was conducted
using cDNA of HUVEC and primers that spanned the 5’
untranslated region and the 3’ untranslated region of the
EPCR gene. In addition to the expected PCR product, a
1221 bp band corresponding to the normal EPCR, a sec-
ond product of 834 bp was noted. The smaller PCR prod-
uct was sequenced, revealing a previously unknown
E. Molina et al. 
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EPCR open reading frame in which part of exon 4 was
absent and exon 3 was spliced directly to the 3’ untrans-
lated region, which we designated as exon 4b, part of
which was translated until a stop codon was encountered
(Figure 1A, B, C). The new open reading frame, therefore,
encoded a truncated form of EPCR (tEPCR), generated by
alternative splicing, whose mature peptide comprised
239 amino acids. Residues 1-183 were identical to the
normally spliced RNA and comprised the signal peptide
and the extracellular region of EPCR. However, residues
184-239 corresponded to a unique C terminus consisting,
in part, of the 3’ untranslated region instead of the trans-
membrane domain and the cytoplasmic tail of EPCR.
This new form, tEPCR, is predicted to be secreted, and
not anchored in the membrane cell, as also suggested by
the experiment performed with COS-7 cells transfected
with EPCR or with tEPCR, both fused with GFP.
Fluorescence microscopy experiments showed that while
the full-length EPCR accumulated in the cell membrane,
this localization pattern was not observed with tEPCR.
This result is consistent with the fact that tEPCR lacks
the transmembrane domain (Figure 1D). We wanted to
know whether the expression of tEPCR is restricted to
HUVEC or whether this alternatively spliced form of
EPCR could also be found at other locations. We detect-
ed tEPCR in the cDNA of the heart, liver, kidneys, pan-
creas, lung, placenta, thymus, small intestine, and spleen,
while it was virtually absent in the cDNA of skeletal
muscle, brain, and leukocytes. Since alternative splicing is
frequently seen in cancer cells, we looked for the pres-
ence of tEPCR in a battery of cDNA from lung cancer cell
lines. Interestingly, cDNA of tEPCR was present in a high
number of samples (Figure 1E), and in some cases, high-
ly expressed (e.g., A549 cDNA in lane 16).
tEPCR interacts with protein C and factor VIIa in a
manner similar to sEPCR
The binding of protein C to tEPCR or sEPCR, previ-
ously captured on a CM5 chip by the anti-EPCR mono-
clonal antibody RCR-2, was studied by surface plasmon
resonance. Binding of protein C to tEPCR was clearly
detected (Figure 2B,D and Table 1). According to the
rate constants, a KDapp of 141 ± 12 nM (mean±SD, n=2)
was calculated for tEPCR, while the KDapp for sEPCR was
177±12 nM (n=2). When factor VIIa was used as the
analyte instead of protein C, again a high affinity inter-
action was detected with tEPCR (66±44 nM; n=2), sim-
ilar to that observed with sEPCR (37±5 nM; n=2; Figure
2A,C and Table 1).
tEPCR inhibits the activation of protein C on the
endothelial surface
The activation of protein C by thrombin on the sur-
face of EA.hy926 cells was studied in the presence or
Truncated EPCR generated by alternative splicing
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Figure 1. Identification of the truncated form of EPCR (tEPCR). (A) Reverse transcription-PCR with primers spanning the 5´and 3´ untrans-
lated regions of the EPCR gene and cDNA from HUVEC (lane 1). M, molecular weight marker (100 bp DNA ladder). Amplicon a, EPCR (1221
bp), amplicon b, tEPCR (834 bp). (B) Intron–exon structure of the EPCR gene and the resultant exonic structure of EPCR and tEPCR. Exons
are identified by Arabic numbers. Initiation and stop codons are marked with an arrow. (C) Nucleotide and predicted amino acid sequence
of tEPCR. Double underlining indicates the signal peptide sequence. The tEPCR-specific sequence is indicated by single underlining. (D)
COS-7 cells were transfected with GFP-fused EPCR or tEPCR, and the localization of the transfectants was analyzed by fluorescence
microscopy. EPCR is located at the surface of the cells (arrows), while tEPCR is not. (E) Reverse transcription-PCR with primers spanning
exons 3–4b of the EPCR gene using 10 µg total cDNA from the heart (1), liver (2), kidney (3), pancreas (4), lung (5), placenta (6), skeletal
muscle (7), brain (8), thymus (9), small intestine (10), spleen (11), and leukocytes (12). cDNA from a library of lung cancer cell lines was
also amplified with specific EPCR gene primers: H446 (13), H510 (14), H1264 (15), A549 (16), H441, HTB51 (17), H676 (18), H727 (19),
H720 (20), H385 (21), and H1299 (22). Amplicon a, EPCR (578 bp), amplicon b, tEPCR (189 bp).
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absence of tEPCR or sEPCR. As expected, sEPCR
markedly reduced the generation of APC by thrombin,
by increasing the Michaelis-Menten constant (Km) of the
activation from 49 nM in its absence to 881 nM in its
presence. tEPCR behaved similarly to sEPCR, and the
Km of protein C activation was 698 nM when the tEPCR
form was present. In all cases, Vmax was essentially
unchanged: 21.6, 32.0, and 28.4 mAU/min, respectively
(Figure 2E).
tEPCR inhibits the anticoagulant activity of APC
We also wanted to reproduce with tEPCR the well-
known inhibitory effect of sEPCR towards the anticoag-
ulant effect of APC on plasma. As previously
described,14 when increasing amounts of sEPCR were
added to plasma supplemented with 1 nM APC, its anti-
coagulant effect was inhibited in a dose-dependent
fashion. The same effect was observed when tEPCR
was used instead of sEPCR, again reinforcing the idea
that both forms of soluble EPCR are functionally similar
(Table 2). Neither sEPCR nor tEPCR exerted any effect
on the activated partial thromboplastin time assay (data
not shown).
tEPCR inhibits the coagulant activity of factor VIIa
We have recently described that sEPCR, upon interac-
tion with the factor VIIa-tissue factor complex, reduces
its coagulant activity by reducing the activation of fac-
tor X.3 Using H727 cells, which provide a tissue factor-
rich surface and enough phospholipids to sustain coag-
ulation, we saw that tEPCR exerted the same effect, to
a similar extent in the presence of tEPCR or sEPCR, the
kcat of the activation of factor X by the factor VIIa-tissue
factor complex was reduced about 4-fold, while the Km
remained essentially the same (Table 3).
tEPCR is found in the supernatant of lung
adenocarcinoma cells
We obtained monoclonal antibodies directed against
the C terminus region of tEPCR, corresponding to part
of the 3’ untranslated region, to set up an immunoas-
say to detect tEPCR specifically, thus avoiding cross-
reaction with sEPCR. To check whether tEPCR could
be detected with this method, we tested the super-
natant of two lung cancer cell lines, A549 and H1264,
which had been shown to express tEPCR at the cDNA
level: in confluent cultures, we detected tEPCR at con-
centrations of 0.27±0.08 and 0.41±0.3 nM, respective-
ly (corresponding to roughly 7% and 26%, respective-
ly, of the total soluble EPCR), thus demonstrating that
this assay will be useful for measuring tEPCR in future
studies of human samples.
tEPCR is found in the supernatant of HUVEC
tEPCR was detected by western blotting with MAVE-
3, a monoclonal antibody specific for tEPCR, in the
supernatant of HUVEC confluent cultures previously
submitted to deglycosylation. The band observed
migrated to the same distance as our deglycosylated
recombinant tEPCR (Figure 3).
Discussion
EPCR is the high affinity receptor for protein C/APC.
EPCR augments the thrombin-thrombomodulin activa-
tion of protein C on endothelial cells. Recently, we and
E. Molina et al. 
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Figure 2. Surface plasmon resonance analysis of the binding of
protein C and factor VIIa to tEPCR or sEPCR and effect of tEPCR
and sEPCR on APC generation. (A-D) tEPCR or sEPCR were cap-
tured to a level of 200 RU on a CM5 chip using RCR-2 monoclonal
antibody. The binding of 1, 5, 15, 45, 90, and 270 nM factor VIIa
and protein C to tEPCR or sEPCR was recorded. A representative
experiment of two independent repeats is shown. Black lines rep-
resent experimental data, gray lines represent fittings. (E) The acti-
vation of protein C on endothelium was assayed in the absence or
presence of 1 µM sEPCR or tEPCR. AU means absorbance units; s
means seconds. 
Table 1. Surface plasmon resonance kinetic rate constants of the interaction of protein C and factor VIIa with tEPCR or sEPCR.
Analyte Ligand Ka1 (M-1 s-1)x105 Kd1 (s-1) Ka2 (s-1) Kd2 (s-1)x10-3 KDapp (nM)
Protein C tEPCR 7.68±1.39 0.189±0.002 8.2±1.6 11.0± 4 141±12
Protein C sEPCR 4.83±0.18 0.156±0.008 6.2±0.1 7.4±0.2 177±12
VIIa tEPCR 8.53±4.35 0.234±0.025 15.2±2.6 3.4±1.1 66±44
VIIa sEPCR 10.40±0.71 0.264±0.007 14.0±0.2 2.3 0.1 37±5
Interactions were fitted to a two-state conformational change kinetic model.    
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others have described that EPCR also binds factor
VII/VIIa.3,15,16 As a consequence, activation of factor X by
the factor VIIa-tissue factor complex is inhibited.3 A sol-
uble form of EPCR, consisting of its extracellular domain,
is detectable in human plasma at levels below 200 ng/mL
in the majority of the population. However, about 20%
of healthy subjects, as well as patients with sepsis, sys-
temic lupus, Wegener’s granulomatosis, and fetal death,
have higher levels.4,5,17-19 The origin of sEPCR has been
attributed to shedding of the membrane-anchored EPCR
by TACE7 and is associated with the presence of the A3
haplotype of the EPCR gene.6 Data from a recent report
by Saposnik et al.11 as well as our own results constitute
enough evidence to state that another soluble form of
EPCR exists, which is generated by alternative splicing,
lacks the cytoplasmic and transmembrane domains and
adds a tail of 56 residues at the C terminus corresponding
to part of the 3’ untranslated region of the EPCR gene.
Alternative splicing eliminates part of exon 4 of the
EPCR gene, which codes for the domains responsible for
anchoring EPCR to the membrane. However, since exons
1-3 are conserved, the entire extracellular fraction is pre-
served in this truncated form of EPCR. The extracellular
region of EPCR is responsible for binding to both protein
C/APC and factor VII/VIIa.3,4 Surface plasmon resonance
experiments reveal that binding of both soluble EPCR
forms to protein C and factor VIIa is similar. tEPCR
inhibits the generation of APC by the thrombin-throm-
bomodulin complex on cell surfaces and inhibits its anti-
coagulant effect on plasma to the same extent as sEPCR.
Finally, the sEPCR-dependent inhibition of factor VIIa
activity towards factor X is also reproduced using tEPCR.
Therefore, the newly incorporated residues at the C ter-
minus of tEPCR, corresponding to the 3’ untranslated
region, do not influence its functions and the soluble
EPCR fraction originated by alternative splicing seems to
be functionally indistinguishable from the fraction origi-
nated by shedding. 
The fact that the tEPCR transcript is not limited to
HUVEC, but is found in cDNA of several organs, such as
the heart, lungs, liver and others, is consistent with the
idea that the mature endothelium is also a source of
tEPCR. Thus, a fraction of the plasma sEPCR levels may
actually correspond to tEPCR. The levels of sEPCR
reported in the literature have been measured by an
immunoassay that can also detect the tEPCR (data not
shown). On the other hand, the fact that the tEPCR tran-
script is present in cDNA of some lung cancer cell lines
and the protein has been detected in the supernatant of
two of them, A549 and H1264, suggests that neoplastic
cells can be a source of tEPCR.
Our research, therefore, sets the stage for future stud-
ies to determine the pathophysiological relevance of
tEPCR, as well as its contribution to the plasma pool of
sEPCR. Even if tEPCR does contribute to the plasma
sEPCR, its pathophysiological significance is unclear. The
role of sEPCR as a thrombotic risk factor is controversial
and although increased plasma levels of sEPCR were
associated with venous thrombosis,6 further studies did
not confirm such an association,8,9 most probably because
the concentration of sEPCR in plasma is not high enough
to compromise protein C activation or APC anticoagu-
lant actions. Furthermore, our finding that sEPCR is also
able to reduce the activity of the factor VIIa-tissue factor
complex,3 if relevant in the physiological setting, would
counterbalance its procoagulant effect.
In summary, we have detected a new variant form of
soluble EPCR which arises from alternative splicing and
shares functional homology with sEPCR. These results
set the basis for future studies aimed at determining
whether or not tEPCR is related to EPCR haplotypes, is
constitutively expressed or is inducible by inflammatory
stimuli, is an important contributor to the total fraction
of sEPCR, or is associated with a higher risk of throm-
bosis.
Truncated EPCR generated by alternative splicing
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Table 2. Effect of tEPCR and sEPCR on the anticoagulant activity of
1 nM APC in human plasma.
Activated partial thromboplastin time, seconds 
sEPCR or tEPCR, nM sEPCR tEPCR
0 43.9±0.4 43.9±0.4
50 41.8±0.2 41.8±0.9 
100 40.5±0.6 41.0±0.5 
250 39.9±0.3 39.7±0.2 
500 39.5±0.2 39.4±0.9 
1000 38.2±0.2 37.9±0.3
The activated partial thromboplastin time without added APC was 33.1 ± 0.4 sec-
onds. Values are the mean ± SD of four determinations.   
Table 3. Effect of tEPCR or sEPCR on the factor VIIa-mediated acti-
vation of factor X.
Km (nM) kcat(s-1) kcat/Km kl (nM)
VIIa+H727 85.5±6.2 6.3±0.7 765.8±134.7 n.a.
VIIa+H727+tEPCR 88.9±6.1 1.5±0.1 168.6±4.4 97.2±16.3
VIIa+H727+sEPCR 97.9±13.9 1.8±0.2 178.9±3.7 78.8±9.8
15-1000 nM factor X was activated with 10 pM factor VIIa in the presence of
1x106/mL H727 cells, with or without 250 nM tEPCR or sEPCR. The
chromogenic activity of factor Xa towards 0.6 mM S-2765 was subsequently
determined. The values of the kinetic constants correspond to the mean±SD of
at least two determinations. Units of kcat/Km are (M-1 s-1 105); n.a., not applicable. 
Figure 3. Detection of tEPCR by western blotting in the supernatant
of HUVEC. The supernatant of confluent HUVEC cultures was degly-
cosylated and, subsequently, 30 µL were submitted to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and western
blotting using MAVE-3, a monoclonal antibody specific for tEPCR.
Thirty milliliters of in-house produced and deglycosylated tEPCR
were also loaded at different concentrations. Lane 1: standards
(molecular weights in kDa are indicated at the left); lane 2: deglyco-
sylated culture medium; lane 3: deglycosylated HUVEC-conditioned
culture medium; lanes 4, 5, and 6: deglycosylated recombinant
tEPCR at concentrations of 10, 5 and 2.5 nM, respectively. 
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